People's Hospital, Peking University, Musculoskeletal Tumor Center, Beijing, 100044, China.
Bone Joint J. 2014 Mar;96-B(3):399-405. doi: 10.1302/0301-620X.96B3.32387.
We report our early experience with the use of a new prosthesis, the Modular Hemipelvic Prosthesis II, for reconstruction of the hemipelvis after resection of a primary malignant peri-acetabular tumour involving the sacroiliac joint. We retrospectively reviewed the outcome of 17 patients who had undergone resection of a pelvic tumour and reconstruction with this prosthesis between July 2002 and July 2010. One patient had a type I+II+III+IV resection (ilium + peri-acetabulum + pubis/ischium + sacrum) and 16 had a type I+II+IV resection (ilium + acetabulum + sacrum). The outcome was assessed at a mean follow-up of 33 months (15 to 59). One patient was alive with disease, 11 were alive without disease and five had died of disease. The overall five-year survival rate was 62.4%. Six patients had a local recurrence. The mean Musculoskeletal Tumour Society score was 58% (33 to 77). Deep infection occurred in two patients, problems with wound healing in five and dislocation in one. For patients with a primary malignant peri-acetabular sarcoma involving the sacroiliac joint, we believe that this new prosthesis is a viable option for reconstruction of the bony defect left following resection of the tumour. It results in a satisfactory functional outcome with an acceptable rate of complications.
我们报告了使用新型假体(模块化半骨盆假体 II 型)重建原发性恶性髋臼周围肿瘤累及骶髂关节切除术后半骨盆的早期经验。我们回顾性分析了 2002 年 7 月至 2010 年 7 月期间 17 例接受骨盆肿瘤切除和该假体重建患者的结果。1 例患者行 I+II+III+IV 型(髂骨+髋臼+耻骨/坐骨+骶骨)切除,16 例行 I+II+IV 型(髂骨+髋臼+骶骨)切除。平均随访 33 个月(15 至 59 个月)时评估结果。1 例患者存活且有疾病,11 例患者存活且无疾病,5 例患者死于疾病。总体 5 年生存率为 62.4%。6 例患者局部复发。肌肉骨骼肿瘤学会评分平均为 58%(33 至 77)。2 例患者发生深部感染,5 例患者发生伤口愈合问题,1 例患者发生脱位。对于原发性恶性髋臼周围肉瘤累及骶髂关节的患者,我们认为这种新型假体是重建肿瘤切除后留下的骨缺损的可行选择。它可获得令人满意的功能结果,并发症发生率可接受。